N.J.--(BUSINESS WIRE)--Aug. 3, 2004--Sentigen Holding
Corp. (NasdaqSC: SGHL) announced today that it has
been awarded a contract by the Technical Support Working
Group (TSWG) - an interagency government office with
representatives from the Departments of Defense, State
and Homeland Security - to develop advanced biotechnology
for the detection of explosives and other threats.
The contract, entitled "Olfactory Receptor Microarray-Based
Sensor for Explosives Detection (ORM-EDS)", will
provide Sentigen with $1.65 million in research funding
over the next 2 years.
Sentigen will conduct research for the development
of a freestanding sensor for the detection of explosive
agents. The sensor is aimed at reproducing the sensitivity,
versatility, and chemical range of the nose. The Company
will be working to isolate, produce, and assemble
mammalian olfactory receptors into microarrays that
would allow the nano-scale monitoring of patterns
of olfactory receptor activation resulting from exposure
to potentially harmful agents.
"We are very pleased to have been selected by
TSWG in the awarding to us of this important research
contract," commented Joseph K. Pagano, Sentigen's
chairman. "We have assembled a multi-disciplinary
team that is in a unique position to perform this
work at the intersection of molecular biology, physical
chemistry, materials science, and nanotechnology."
Nanotechnology is the engineering of functional materials,
devices, and systems on the scale of atoms and molecules.
The Company believes that upon success, the work under
this contract has the potential to meet critical homeland
security needs, as well as to complement its existing
technologies to yield applications in areas such as
drug discovery and diagnostics.
About Sentigen Holding Corp.
We are a holding company conducting business through
two wholly-owned operating subsidiaries, Cell &
Molecular Technologies, Inc. ("CMT"), and
Sentigen Biosciences, Inc. CMT provides contract research
and development services and manufactures specialty
cell culture media, reagents and other research products
for companies engaged in the drug discovery process.
Sentigen Biosciences is primarily engaged in the development
and commercialization of novel bioassay systems that
elucidate the underlying biology of protein-protein
interactions. Sentigen Biosciences is initially targeting
its Tango(TM) Assay System to address the functionalization
of G protein-coupled receptors (GPCRs) for pharmaceutical
drug discovery and development. Sentigen Biosciences
has filed patent applications on its Assay System
and expects to file additional patent applications
on this technology in the future